186 related articles for article (PubMed ID: 33478544)
21. Proton Therapy for HPV-Associated Oropharyngeal Cancers of the Head and Neck: a De-Intensification Strategy.
Taku N; Wang L; Garden AS; Rosenthal DI; Gunn GB; Morrison WH; Fuller CD; Phan J; Reddy JP; Moreno AC; Spiotto MT; Chronowski G; Shah SJ; Mayo LL; Gross ND; Ferrarotto R; Zhu XR; Zhang X; Frank SJ
Curr Treat Options Oncol; 2021 Jun; 22(6):54. PubMed ID: 34086150
[TBL] [Abstract][Full Text] [Related]
22. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
[TBL] [Abstract][Full Text] [Related]
23. Establishing Cost-Effective Allocation of Proton Therapy for Breast Irradiation.
Mailhot Vega RB; Ishaq O; Raldow A; Perez CA; Jimenez R; Scherrer-Crosbie M; Bussiere M; Taghian A; Sher DJ; MacDonald SM
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):11-18. PubMed ID: 27084617
[TBL] [Abstract][Full Text] [Related]
24. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy.
Bagley AF; Ye R; Garden AS; Gunn GB; Rosenthal DI; Fuller CD; Morrison WH; Phan J; Sturgis EM; Ferrarotto R; Wu R; Liu AY; Frank SJ
Radiother Oncol; 2020 Jan; 142():133-139. PubMed ID: 31431373
[TBL] [Abstract][Full Text] [Related]
25. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit.
Nangia S; Gaikwad U; Noufal MP; Sawant M; Wakde M; Mathew A; Chilukuri S; Sharma D; Jalali R
Radiat Oncol; 2023 Jul; 18(1):121. PubMed ID: 37468950
[TBL] [Abstract][Full Text] [Related]
26. Impact of model and dose uncertainty on model-based selection of oropharyngeal cancer patients for proton therapy.
Bijman RG; Breedveld S; Arts T; Astreinidou E; de Jong MA; Granton PV; Petit SF; Hoogeman MS
Acta Oncol; 2017 Nov; 56(11):1444-1450. PubMed ID: 28828923
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of cochlear dose reduction by proton beam therapy for medulloblastoma in childhood.
Hirano E; Fuji H; Onoe T; Kumar V; Shirato H; Kawabuchi K
J Radiat Res; 2014 Mar; 55(2):320-7. PubMed ID: 24187330
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy.
Zhou GQ; Wu CF; Zhang J; Mao YP; Tang LL; Chen L; Guo R; Ma J; Sun Y
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1382-1391. PubMed ID: 29804816
[TBL] [Abstract][Full Text] [Related]
29. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.
Sio TT; Lin HK; Shi Q; Gunn GB; Cleeland CS; Lee JJ; Hernandez M; Blanchard P; Thaker NG; Phan J; Rosenthal DI; Garden AS; Morrison WH; Fuller CD; Mendoza TR; Mohan R; Wang XS; Frank SJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1107-14. PubMed ID: 27354125
[TBL] [Abstract][Full Text] [Related]
30. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
31. Impact of setup and range uncertainties on TCP and NTCP following VMAT or IMPT of oropharyngeal cancer patients.
Hamming-Vrieze O; Depauw N; Craft DL; Chan AW; Rasch CRN; Verheij M; Sonke JJ; Kooy HM
Phys Med Biol; 2019 Apr; 64(9):095001. PubMed ID: 30921775
[TBL] [Abstract][Full Text] [Related]
32. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
Konski A; Speier W; Hanlon A; Beck JR; Pollack A
J Clin Oncol; 2007 Aug; 25(24):3603-8. PubMed ID: 17704408
[TBL] [Abstract][Full Text] [Related]
33. Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
Zhang W; Zhang X; Yang P; Blanchard P; Garden AS; Gunn B; Fuller CD; Chambers M; Hutcheson KA; Ye R; Lai SY; Radwan MAS; Zhu XR; Frank SJ
Radiother Oncol; 2017 Jun; 123(3):401-405. PubMed ID: 28549794
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer.
Manzar GS; Lester SC; Routman DM; Harmsen WS; Petersen MM; Sloan JA; Mundy DW; Hunzeker AE; Amundson AC; Anderson JL; Patel SH; Garces YI; Halyard MY; McGee LA; Neben-Wittich MA; Ma DJ; Frank SJ; Whitaker TJ; Foote RL
Radiother Oncol; 2020 Jun; 147():64-74. PubMed ID: 32234612
[TBL] [Abstract][Full Text] [Related]
35. Advances in radiation oncology for the management of oropharyngeal tumors.
Gunn GB; Frank SJ
Otolaryngol Clin North Am; 2013 Aug; 46(4):629-43. PubMed ID: 23910474
[TBL] [Abstract][Full Text] [Related]
36. Model-based approach for quantitative estimates of skin, heart, and lung toxicity risk for left-side photon and proton irradiation after breast-conserving surgery.
Tommasino F; Durante M; D'Avino V; Liuzzi R; Conson M; Farace P; Palma G; Schwarz M; Cella L; Pacelli R
Acta Oncol; 2017 May; 56(5):730-736. PubMed ID: 28281862
[TBL] [Abstract][Full Text] [Related]
37. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of proton versus photon radiation therapy with respect to the risk of growth hormone deficiency in children.
Mailhot Vega R; Kim J; Hollander A; Hattangadi-Gluth J; Michalski J; Tarbell NJ; Yock TI; Bussiere M; MacDonald SM
Cancer; 2015 May; 121(10):1694-702. PubMed ID: 25641407
[TBL] [Abstract][Full Text] [Related]
39. Robust Intensity Modulated Proton Therapy (IMPT) Increases Estimated Clinical Benefit in Head and Neck Cancer Patients.
van Dijk LV; Steenbakkers RJ; ten Haken B; van der Laan HP; van 't Veld AA; Langendijk JA; Korevaar EW
PLoS One; 2016; 11(3):e0152477. PubMed ID: 27030987
[TBL] [Abstract][Full Text] [Related]
40. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
Moreno AC; Frank SJ; Garden AS; Rosenthal DI; Fuller CD; Gunn GB; Reddy JP; Morrison WH; Williamson TD; Holliday EB; Phan J; Blanchard P
Oral Oncol; 2019 Jan; 88():66-74. PubMed ID: 30616799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
